Peptides DB
Research-centric peptide and protocol reference hub

Teriparatide (PTH 1-34) record · updated 8h ago

Healing & recoveryMetabolic & appetiteGrade A · human clinicalResearch use only
All 4 studiesJump to the evidenceCompare
What is Teriparatide (PTH 1-34) used for?

PTH(1-34) | Bone-Building Anabolic Peptide

Primarily researched for · Healing & recovery

Development stage

where Teriparatide (PTH 1-34) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 25 registered trials. It describes the research record, not a recommendation.

Identity
NameTeriparatide (PTH 1-34)
Full name—
Sequence—
ClassHealing
Research levelExtensively Studied
Discovered byCurated master list · 2026
Pharmacology
Mechanism—
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence—
Effect profile · 0–5
Healing & recovery: Healing 5.0, Muscle 1.0, Metabolic 2.0, Neuro 0.0, Sleep 0.0, Immune 1.0, Skin 1.0Healing & recovery — 5.0 / 5Muscle & body comp — 1.0 / 5Metabolic & appetite — 2.0 / 5Inflammation & immune — 1.0 / 5Skin & aesthetics — 1.0 / 5HealingMuscleMetabolicNeuroSleepImmuneSkin5.01.02.00.00.01.01.0
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o mini over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Jul 27, 2026. How this works →
Research stats
Total studies4
Human / animal / cellular2 / 2 / 0
Highest trial phasePreclinical
Years covered2023–2026
Latest study12d ago
Publication history
20232026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

4 rowsOpen in the library →
StudyTypeYearSummary depth
Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial.
Finding36.9% of participants in the teriparatide plus zoledronic acid group had incident fractures vs 36.4% in the standard care group, absolute risk reduction -1.57%, 95% CI -9.90% to 5.89%, hazard ratio 0.97, 95% CI 0.68 to 1.38.
Human2026Full text read0.90
Differential effects of PTH (1-34), PTHrP (1-36) and abaloparatide on the murine osteoblast transcriptome
FindingPTH(1-34) regulated 367 genes, including 194 unique genes.
Animal2023Full text read0.70
Transcriptional reprogramming during human osteoclast differentiation identifies regulators of osteoclast activity
Finding8446 differentially expressed genes grouped into eight temporal patterns.
Human2023Full text read0.80
Bone response to intermittent parathyroid hormone (PTH) is both genetic and sex specific
FindingNot reported in abstract.
Animal2026Full text read0.70